Defects in surfactant synthesis: clinical implications

Pediatr Clin North Am. 2006 Oct;53(5):911-27, ix. doi: 10.1016/j.pcl.2006.08.006.

Abstract

Since the original description of deficiency of the pulmonary surfactant in premature newborn infants by Avery and Mead in 1959, respiratory distress syndrome has most commonly been attributed to developmental immaturity of surfactant production. Studies of different ethnic groups, gender, targeted gene ablation in murine lineages, and recent clinical reports of monogenic causes of neonatal respiratory distress syndrome have demonstrated that genetic defects disrupt pulmonary surfactant metabolism and cause respiratory distress syndrome, especially in term or near-term infants and in older infants, children, and adults. In contrast to developmental causes of respiratory distress, which may improve as infants and children mature, genetic causes result in both acute and chronic (and potentially irreversible) respiratory failure.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Humans
  • Infant, Newborn
  • Pulmonary Surfactant-Associated Proteins / deficiency*
  • Pulmonary Surfactant-Associated Proteins / metabolism
  • Pulmonary Surfactants / pharmacology*
  • Respiratory Distress Syndrome, Newborn / metabolism*
  • Respiratory Distress Syndrome, Newborn / therapy

Substances

  • Pulmonary Surfactant-Associated Proteins
  • Pulmonary Surfactants